期刊文献+

复方制剂有关物质研究及其对产品优化的作用 被引量:2

Impurity Control for Compound Preparation and its Impact on Product Optimization
下载PDF
导出
摘要 复方制剂系指含有多个主药成分(≥2个)的制剂,由于其主药成分较多,除了各原料药的杂质和生产贮存过程中产生的杂质外,还包括主药与主药、主药与辅料之间相互作用产生的降解产物。因此,复方制剂的杂质研究相较于单方制剂更为复杂。本文根据实际案例,梳理了复方制剂有关物质研究和产品优化的基本思路。从杂质分析预测、复方制剂有关物质初步检测方法建立、方法优化、杂质谱研究、杂质归属研究、产品优化等各个步骤逐一阐述,为复方制剂基于有关物质研究开展质量优化的整体流程和思路提供参考。 The compound preparation contains more than one APIs,the sources and types of impurities involved are complex and diverse,and the impurity study is more complex than that of the monotherapeutic preparation,including not only the impurities introduced by each API,the deg-radation products produced by each component during preparation and storage,and the degradation products generated by the possible interactions between the APIs,the API and the excipients.This paper aims to sort out the basic ideas of studying related substances and product optimization of compound preparations according to actual cases,including impurity prediction,preliminary analysis method establishment,analysis method optimi-zation,impurity profile study,impurity attribution study and product optimization,in order to provide reference for the quality optimization of com-pound preparations.
作者 唐丽莉 黄慧萍 Tang Lili;Huang Huiping(Fudan University,Shanghai,200433)
机构地区 复旦大学
出处 《当代化工研究》 CAS 2023年第19期188-190,共3页 Modern Chemical Research
关键词 有关物质 杂质 复方制剂 产品优化 related substance impurities compound preparation product optimization
  • 相关文献

参考文献5

二级参考文献47

  • 1任丽萍,田芹,潘灿平.丁草胺原药中主要杂质的GC-MS定性分析[J].农药,2005,44(2):74-75. 被引量:4
  • 2国家食品药品监督管理局.化学药物杂质研究的技术指导原则[S].2005. 被引量:7
  • 3..http://www.fda.gov/Safety/Recalls/Enforce-mentReports/default.htm,. 被引量:1
  • 4McMahon AW,Pratt RG,Harnmad TA.Description of hypersen-sitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008 [ J].Phann Epidemiol Drug Saf,2010,19(9):921-933. 被引量:1
  • 5Mtiller L,Mauthe RJ,Riley CM.A rationale for determining,testing,and controlling specific impurities in pharmaceuticals that possess potential for genotoxieity [ J ].Regul Toxicol Pharmacol.2006,44(3):198-211. 被引量:1
  • 6..http://www.cde.org.cn/dzkw.do? method = largePage&id = 311390,. 被引量:1
  • 7Gorog S.Identification and determination of impurities in drugs [ M ].Amsterdam(Netherlands):Elsevier Science,2000:506-547. 被引量:1
  • 8Pavon JLP,M.del NS,Laespada MEF.Analysis of class 1 resid-ual solvents in pharmaceuticals using headspace-programmed tern-perature vaporization-fast gas chromatography-mass spectrometry [J].J Chromatogr A,2007,1141(1):123-130. 被引量:1
  • 9Saavedra L,Huidobro AL,Garcia A.CE as orthogonal technique to HPLC for alprazolam degradation product identification[ J].E-lectrophoresis,2006,27(12):2360-2366. 被引量:1
  • 10Wang X,Li W,Rasmussen HT.Orthogonal method development using hydrophilic interaction chromatography and reversed-phase high-performance liquid chromatography for the determination of pharmaceuticals and impurities[ J ].J Chromatogr A,2005,1083(1-2):58-62. 被引量:1

共引文献33

同被引文献21

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部